GlassScriptPhysician profile
Ann Patrick G Meagher
NPI 1063072825
$3,455.27
in general payments reported to CMS, 2019-2025
21 companies · $1,211 in 2025
The $1,211 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $324 · 2022: $649 · 2023: $595 · 2024: $675 · 2025: $1,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,481.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $823.91 | 2021-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $582.38 | 2023-2025 | Zoryve |
| Incyte Corporation | $434.76 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $296.05 | 2023-2025 | Dupixent, Libtayo |
| Abbvie INC. | $212.82 | 2022-2024 | |
| Organon LLC | $208.86 | 2024-2025 | Vtama |
| Genzyme Corporation | $153.14 | 2022-2025 | |
| Organogenesis INC. | $142.60 | 2024 | Cygnus Dual, Puraply Am |
| Journey Medical Corporation | $110.74 | 2022 | |
| Pfizer INC. | $97.63 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $69.78 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $66.71 | 2023-2024 | Sotyktu |
| Leo Pharma INC. | $50.82 | 2022-2025 | Anzupgo |
| Boston Scientific Corporation | $46.68 | 2025 | Wavewriter Alpha Prime 16 |
| Novartis Pharmaceuticals Corporation | $31.39 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $29.75 | 2023 | Ycanth |
| Sun Pharmaceutical Industries INC. | $22.27 | 2024 | |
| Dermavant Sciences, INC. | $21.72 | 2023 | Vtama |
| Becton, Dickinson and Company | $20.20 | 2024 | Venclose Maven Catheter |
| Biofrontera INC. | $19.27 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Janssen Biotech, INC. | $13.79 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Patrick Meagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.